Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
Allakos Inc. (ALLK)
Last allakos inc. earnings: 11/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.allakos.com/investor-relations
Company Research
Source: GlobeNewswire
– Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– Subcutaneous AK006 was well-tolerated with a favorable safety profile –– Top-line Phase 1 results of Intravenous AK006 in patients with CSU are expected in early Q1 of 2025 – SAN CARLOS, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced results from the Phase 1 study of subcutaneous AK006 in healthy volunteers. AK006 is a Siglec-6 monoclonal antibody that selectively inhibits mast cells. Inappropriate activation of mast cells has been identified as a pathogenic driver of multiple diseases, including chronic spontaneous urticaria, food allergy and asthma. Phase 1 Study Results of Subcutaneous AK006 in Healthy Volunteers Bioavailability of subcutaneous AK006 was approximately 77%.Subcutaneous administered AK006 showed an estimated ha
Show less
Read more
Impact Snapshot
Event Time:
ALLK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLK alerts
High impacting Allakos Inc. news events
Weekly update
A roundup of the hottest topics
ALLK
News
- Kuehn Law Encourages Investors of Allakos Inc. to Contact Law FirmPR Newswire
- All You Need to Know About Allakos (ALLK) Rating Upgrade to Buy [Yahoo! Finance]Yahoo! Finance
- Allakos Provides Business Update and Reports Third Quarter 2024 Financial ResultsGlobeNewswire
- Allakos Inc. (NASDAQ: ALLK) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $3.00 price target on the stock.MarketBeat
ALLK
Earnings
- 11/6/24 - Beat
ALLK
Sec Filings
- 12/9/24 - Form 4
- 12/9/24 - Form 4
- 12/6/24 - Form 144
- ALLK's page on the SEC website